Tempest Therapeutics (TPST) Competitors $7.11 -0.23 (-3.13%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. CCCC, ZNTL, ALEC, TNXP, SLN, COYA, BHST, IMUX, ELUT, and ZURAShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include C4 Therapeutics (CCCC), Zentalis Pharmaceuticals (ZNTL), Alector (ALEC), Tonix Pharmaceuticals (TNXP), Silence Therapeutics (SLN), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), Immunic (IMUX), Elutia (ELUT), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. C4 Therapeutics Zentalis Pharmaceuticals Alector Tonix Pharmaceuticals Silence Therapeutics Coya Therapeutics BioHarvest Sciences Immunic Elutia Zura Bio C4 Therapeutics (NASDAQ:CCCC) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of CCCC or TPST? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, CCCC or TPST? C4 Therapeutics has a beta of 3.11, indicating that its share price is 211% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.34, indicating that its share price is 334% less volatile than the S&P 500. Does the MarketBeat Community believe in CCCC or TPST? Tempest Therapeutics received 75 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 65.38% of users gave Tempest Therapeutics an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% Tempest TherapeuticsOutperform Votes10265.38% Underperform Votes5434.62% Does the media favor CCCC or TPST? In the previous week, Tempest Therapeutics had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.82 beat Tempest Therapeutics' score of 0.07 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Very Positive Tempest Therapeutics Neutral Is CCCC or TPST more profitable? Tempest Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Tempest Therapeutics N/A -187.44%-82.61% Which has stronger valuation & earnings, CCCC or TPST? Tempest Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M3.27-$132.49M-$1.51-1.09Tempest TherapeuticsN/AN/A-$29.49M-$19.51-0.36 Do analysts prefer CCCC or TPST? C4 Therapeutics presently has a consensus price target of $12.50, indicating a potential upside of 662.20%. Tempest Therapeutics has a consensus price target of $30.00, indicating a potential upside of 321.94%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryC4 Therapeutics beats Tempest Therapeutics on 12 of the 17 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.02M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-4.657.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book5.126.516.774.25Net Income-$29.49M$143.21M$3.22B$248.23M7 Day Performance-9.89%3.97%3.26%3.29%1 Month Performance-29.16%0.37%0.02%2.42%1 Year Performance-84.24%2.60%18.01%5.54% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics2.214 of 5 stars$7.11-3.1%$30.00+321.9%-84.2%$25.02MN/A-4.6520Upcoming EarningsCCCCC4 Therapeutics2.3666 of 5 stars$1.40+12.0%$12.50+792.9%-74.0%$99.39M$35.58M-0.82150Upcoming EarningsNews CoverageZNTLZentalis Pharmaceuticals1.9358 of 5 stars$1.36+5.4%$8.24+506.2%-87.2%$97.66M$67.43M-0.55160Upcoming EarningsNews CoverageALECAlector3.6465 of 5 stars$0.97+5.8%$3.50+259.6%-76.4%$96.45M$100.56M-0.57270Upcoming EarningsPositive NewsTNXPTonix Pharmaceuticals2.3879 of 5 stars$14.96-4.8%$585.00+3,810.4%-96.9%$96.27M$10.09M0.0050Short Interest ↑SLNSilence Therapeutics2.3347 of 5 stars$3.20+1.9%$40.67+1,170.8%-83.1%$95.78M$43.26M-2.04100News CoverageCOYACoya Therapeutics2.0037 of 5 stars$5.71+8.6%$17.00+197.7%-27.2%$95.50M$3.55M-8.786Upcoming EarningsAnalyst ForecastNews CoverageHigh Trading VolumeBHSTBioHarvest SciencesN/A$5.81+2.8%$13.00+123.8%N/A$95.43M$25.19M-4.65N/AGap DownIMUXImmunic2.4713 of 5 stars$0.99+0.9%$13.20+1,234.5%-21.4%$94.77MN/A-0.8070Analyst ForecastNews CoverageGap DownELUTElutia3.2805 of 5 stars$2.30-0.9%$9.00+291.3%-16.6%$93.70M$24.38M-0.88180Upcoming EarningsShort Interest ↑Gap DownZURAZura Bio3.1234 of 5 stars$1.37+11.4%$14.67+970.6%-63.9%$93.67MN/A-2.583Upcoming EarningsShort Interest ↓News CoveragePositive News Related Companies and Tools Related Companies CCCC Alternatives ZNTL Alternatives ALEC Alternatives TNXP Alternatives SLN Alternatives COYA Alternatives BHST Alternatives IMUX Alternatives ELUT Alternatives ZURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TPST Stock Free TPST Stock Alerts